← Eichor
Study identifier: NCT05599347 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease

Condition: Crohn's Disease Relapse · Biological Substance; Adverse Effect  ·  Sponsor: Rambam Health Care Campus

PhasePhase 2
Planned participants180
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a randomized placebo-controlled trial in Crohn's disease patients before initiation of anti-tumor necrosis factor-α (anti-TNF) therapy that aims to test the effect of a pre-treatment short course of azithromycin therapy on immunogenicity

This description comes directly from the study's public registry record.

Talk to the study team

Haggai Bar-Yosef, MD  ·  050-2064878  ·  h_bar-yoseph@rmc.gov.il

Anastasia Weis, MD  ·  A_WEIS@rambam.health.gov.il

Always discuss trial participation with your own doctor first.

Locations (9)

Soroka University Medical CenterBeersheba, IsraelRecruiting
Bnei ZionHaifa, IsraelRecruiting
Carmel Medical CenterHaifa, IsraelRecruiting
Rambam Health Care CampusHaifa, IsraelRecruiting
Wolfson Medical CenterHolon, IsraelRecruiting
Hadassah Medical CenterJerusalem, IsraelRecruiting
Shaare ZedekJerusalem, IsraelRecruiting
ZvulunKiryat Bialik, IsraelRecruiting
Rabin Medical CenterPetah Tikva, IsraelRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05599347